| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Hydroxyrubicin (1–10 μM, 30 min) induces topoisomerase II-mediated DNA breaks in human c-myc initiating DNA[1]. Hydroxyrubicin (2.5–10 μM, 30 min) induces concentration-dependent DNA unwinding[1]. Hydroxyrubicin (1 h) showed slightly stronger cytotoxicity than doxorubicin in sensitive KB3.1 cell lines (IC50: 0.35 μM and 0.8 μM), and 20 times more cytotoxic than doxorubicin in KB-V1 cells (IC50: 2 μM and 40 μM)[1]. In both KB3.1 and KB-V1 cells, the accumulation of hydroxyrubicin (0-10 μM, 1 h) was higher than that of doxorubicin (5-fold higher in KB3.1 cells and 2-fold higher in KB-V1 cells); however, in resistant cells, the accumulation of hydroxyrubicin was 6-7 times lower than that in sensitive cells[1]. Compared with doxorubicin, hydroxyrubicin (0-10 μM) induced slightly more DNA single-strand breaks (SSBs) and DNA-protein crosslinks (DPCs), and protein linker breaks were detected in both KB3.1 and KB-V1 cells[1].
|
|---|---|
| ln Vivo |
Hydroxyrubicin (25–79.1 mg/kg, intravenous injection, once a week for 11 weeks) significantly reduced acute toxicity and cardiotoxicity in mice by enhancing the C-3' dose of doxorubicin, while maintaining antitumor activity in the P388/Dox xenograft model [2].
|
| Animal Protocol |
Animal/Disease Models: Healthy ICR Swiss mice[2].
Doses: 79.1 mg/kg Route of Administration: I.v., once Experimental Results: Significant reduction in granulocytes. Animal/Disease Models: Chronic cardiotoxicity was induced in healthy ICR Swiss mice through repeated administration[2]. Doses: 12 mg/kg Route of Administration: I.v., once weekly for 11 weeks Experimental Results: Mild lesions were observed in 5 out of 10 mice. The degree of myocardial fibrosis was relatively mild. Animal/Disease Models: The model was established using male BDF1 mice (weighing 18-22 g) by intraperitoneal injection of 1×106 P388/Dox leukemia cells (drug-resistant strain)[2]. Doses: 25 mg/kg, 37.5 mg/kg, 50.0 mg/kg Route of Administration: I.v., once Experimental Results: Showed activity in the range of 25-50 mg/kg and no toxicity or death. |
| References |
| Molecular Formula |
C27H28O12
|
|---|---|
| Molecular Weight |
544.50
|
| CAS # |
73113-90-3
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8365 mL | 9.1827 mL | 18.3655 mL | |
| 5 mM | 0.3673 mL | 1.8365 mL | 3.6731 mL | |
| 10 mM | 0.1837 mL | 0.9183 mL | 1.8365 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
